Роль эндотелиальных и плазменных факторов свертывания крови и факторов ангиогенеза в развитии сосудистых осложнений при сахарном диабете 2-го типа
Диссертация
Полученные результаты подтверждают существование выраженных нарушений свертывающей системы крови у больных СД 2 с различной степенью выраженности сосудистых осложнений. Имеющиеся нарушения подтверждают необходимость применения профилактических мероприятий с назначением антитромбоцитарных препаратов для снижения риска развития сосудистых катастроф у больных СД. Полученные результаты относительно… Читать ещё >
Содержание
- ГЛАВА I. Обзор литературы
- 1. Система гемостаза при сахарном диабете
- 1. 1. Механизм гемостаза
- 1. 2. Нарушения системы гемостаза при сахарном диабете 2 типа
- 1. 2. 1. РАН
- 1. 2. 2. Фактор VII
- 1. 2. 3. Фибриноген
- 1. 2. 4. Другие компоненты каскада коагуляции
- 1. 2. 5. Ингибиторы коагуляции
- 1. 2. 6. Компоненты системы фибринолиза
- 1. 2. 7. Ингибиторы фибринолиза
- 1. 2. 8. Тромбоциты и тромбоцитарные лиганды
- 1. 2. 9. Возможности медикаментозной коррекции нарушений гемостаза при сахарном диабете
- 1. Система гемостаза при сахарном диабете
- 2. Система ангиогенеза при сахарном диабете
- 2. 1. Физиологический ангиогенез
- 2. 2. Система ангиогенеза при сахарном диабете
- 2. 2. 1. Роль VEGF в развитии диабетической ретинопатии
- 2. 2. 2. Роль VEGF в развитии диабетической нефропатии
- 2. 2. 3. Роль VEGF в развитии диабетической полинейропатии
- 2. 2. 4. Роль VEGF в развитии макрососудистых осложнений при СД
- 2. 2. 5. Возможности терапевтического воздействия на систему ангиогенеза при сахарном диабете
- 1. Клиническая характеристика больных
- 2. Коагулограмма
- 3. Определение факторов и ингибиторов свертывания крови — VII, VIII, X, vWf, протеина С, протеина S
- 4. Оценка системы ангиогенеза
- 4. 1. Выделение мононуклеарных лейкоцитов из периферической крови
- 4. 2. Выделение тотальной клеточной РНК
- 4. 3. Анализ экспрессии мРНК фактора роста сосудов УЕвР и рецепторов к фактору роста сосудов РЬТ-1 и К1Ж методом ОТ/ПЦР
- 5. Статистический анализ
- 1. Клиническая характеристика обследованных больных
- 2. Оценка состояния свертывающей системы крови у больных с различной степенью выраженности нарушений углеводного обмена и микро- и макрососудистых осложнений
- 2. 1. Оценка состояния свертывающей системы крови по параметрам рутинной коагулограммы
- 2. 2. Факторы свертывания
- 2. 3. Ингибиторы коагуляции
- 3. Система ангиогенеза
- 1. Исследование состояния системы свертывания крови
- 2. Система ангиогенеза
Список литературы
- Александрова И.Т., Ильин В. Н. и соавт. Гемореология и гемостаз при остром тромбозе магистральных вен.// Сов. Медицина 1985 № 7, сс. 82−86.
- Балаболкин М.И. Патогенез и механизм развития ангиопатий при сахарном диабете // Кардиология -2000 № 10. сс. 74−87.
- Балаболкин М. И Диабетология. М., Медицина, 2000.
- Балуда М.В. Медикаментозная коррекция антитромбогенной активности сосудистой стенки у больных ишемической болезнью сердца и сахарным диабетом // Диссертация на соискание ученой степени доктора медицинских наук, М., 1993
- Балуда В.П., Балуда М. В., Гольдберг А. П., Салманов П.Л., J.W. ten Cate Претромботическое состояние тромбоцитов и его профилактика // М. -Амстердам 1999, сс. 213−216.
- Балуда В.П., Деянов И. И. Балаболкин М.И. и соавт. Сосудисто-тромбоцитарное звено системы гемостаза больных сахарным диабетом // Проблемы эндокринологии 1986 — № 2, сс. 32−35.
- Вавилова Т.В. Гемостазиология в клинической практике. // С-Пб, 2005 -с. 60−63.
- Гланц С. Медико-биологическая статистика // М. Практика, 1999.
- Дедов И.И., Шестакова М. В. Сахарный диабет. Руководство для врачей. М., Универсум Паблишинг, 2003.
- Клиническая биохимия. Под ред. акад РАМН Ткачука В. А., М., Гэотар медицина, 2002.
- Коломеец М.Ю., Хухлина О. С., Воевидка О. С. Состояние системы гемостаза у больных с хроническим холециститом и сопутствующим сахарным диабетом. Укр. Мед. Журнал. -2004 № 4 (42).
- Лапотников В.А., Моисеев С. И. Роль системы гемостаза в развитии сосудистых поражения при сахарном диабете // Тер. Архив 1988 -№ 9, сс. 31−35.
- Луценко С.В., Киселев С. М., Северин С. Е. Достижения и перспективы онкологии. Гомель., УО «Гомельский государственный университет им. Франциска Скорины», 2003 г.
- Мамедгасанов P.M., Мазовецкий А. Г., Семавин И. Е. и соавт. Особенности нарушений в системе гемостаза у больных инсулиннезависимым типом сахарного диабета с ангиопатиями сосудов нижних конечностей //Тер. Архив 1989 — № 9, сс. 35−40.
- Михайлова Е.В., Чиркова Л. Д., Балаболкин М. И., Клебанова Е. М. Применение пиявита при сахарном диабете // Сахарный диабет 1999-№ 2, сс. 27−30.
- Нелаева Л.А., Бышевский A.M., Трошина И. А., Журавлева Г. Д. Перекисное окисление липидов и гемостаз у больных инсулинозависимым сахарным диабетом // Проблемы эндокринологии1998, 44 № 5, сс. 10−14.
- Соколов Е.И., Балаболкин М. И., Балуда М. В. и соавт. Система гемостаза в течении диабетической ретинопатии // Сов. Медицина -1985 -№ 11, сс. 13−16.
- Степанян М.Л. Значение нарушений микроциркуляции и гемостаза в патогенезе диабетических ангиопатий // Учен. Записки СПГМУ им. Акад. И. П. Павлова, 1999 № 1- сс. 30−37.
- Степанян М.Л. Структурные изменения тромбоцитов при аллоксановом диабете, как показатели их активации в сосудистом русле и особенностей морфообразования // Цитология, том41 № 21 999, сс. 122−131.
- Abaci A., Yilmaz Y., Caliskan M. ct al. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes // Throm Res. 2005- 116(6): 465−70.
- Abrahamian H. Platelet aggregation inhibitors in diabetes mellitus. // Acta Med Austriaca 1999- 26(5): 137−141.
- Acang N., Jalil F.D. Hypercoagulation in diabetes mellitus. // Southeast Asian J Trop Med Public Health 1993- 24 Suppl 1: 263−266.
- Aiello L.P., Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications. // Kidney Int. Suppl. 2000 Sep- 77: SI 13−9.
- Alakhverdian R., Koev D. Fibrinogen-fibrin degradation products in diabetes mellitus. // Vutr Boles 1987- 26(6): 74−76.
- Altunbas H., Karayalcin U., Undara L. Glycemic control and coagulation inhibitors in diabetic patients. // Haemostasis 1998 Nov-Dec- 28(6): 307 312.
- Aoki I., Shimoyama K., Aoki N. et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. // J Am Coll Cardiol 1996 Mar 1- 27(3): 560−566.
- Aso Y., Fujiwara Y., Tayama K et al. Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. // Clin Chim Acta 2000 Nov- 301(1−2): 135−145.
- Aso Y., Matsumoto S., Fujiwara Y. et al. Impared fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. // Metabolism 2002 Apr- 51(4): 471−476.
- Avellone G., di Garbo V., Cordova R., Rotolo G. et al. Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients. // Metabolism 1997 Aug- 46(8): 930−934.
- Barleon B., Sozzani S., Zhou D., Weich H., Mantovani A. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF)is mediated via the VEGF receptor flt-1. // Blood. 1996 Apr 15−87(8) 333 643.
- Bellart J., Gilabert R., Fontcuberta J. et al. Coagulation and fibrinolysis parameters in normal pregnancy and in gestational diabetes. // Am J Perinatol 1998 Aug- 15(8): 479−486.
- Bendl J., Kvasnicka J., Umfaulova A. et al. Hemostasis and levels of cytoadhesion molecules in gestational diabetes.// Ceska Gynekol 1999 Apr- 64(2): 83−86.
- Bortoloso E., Del Prete D., Dalla Vestra M. et al Quantative and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes // Eur J Endocrinol. 2004 Jun- 150(6): 799 807.
- Boyum A. (1968) Scan. J. Clin. Lab. Invest., 21, Suppl, 97, p. 77.
- Bruno G., Merletti F., Biggeri A. et al. Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study//Diabetologia 2005 Mar- 48(3):437−34.
- Carr M. Diabetes mellitus: a hypercoagulable state. // J Diabetes Complications 2001 Jan-Feb- 15(1): 44−54.
- Cefalu W., Schneider D., Carlson H., Migdal P., Lim L. et al. Effect of combination Glipizide GITS/ Metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. // Diabetes Care 25:2123−2128, 2002.
- Ceriello A., Giugliano D., Quatraro A. et al. Heparin preserves antitrombin III biological activity from hyperglycaemia-induced alterations in insulin-dependent diabetes. // Haemostasis 1986 — 16(6): 458−464.
- Ceriello A., Giacomello R., Stel G. et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. // Diabetes 1995 Aug- 44(8): 924−928.
- Ceriello A., Taboga C., Tonutti L. et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. // Diabetologia 1996 Apr- 39(4): 469−473.
- Cha D.R., Kim N.H., Yoon J.W., Jo S.K., Cho W.Y., Kim H.K., Won N.H. Role of vascular endothelial growth factor in diabetic nephropathy. // Kidney Int Suppl 2000 Sep- 77: S104−12.
- Chan NN., Fuller JH., Rubens M. et al. Von Willebrand factor in type 1 diabetes: its production and coronary artery calcification //Med Sei Monit 2003 Jul- 9(7): CR297−303.
- Chelly J., Kahn A. RT-PCR and mRNA quantification. In: The Polymerase Chain Reaction. Mullis K.B., Ferre F., Gibbs R.A., ed. Birkhauser: Boston -Basel Berlin, 1994.
- Chomszynski P. and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction // Anal. Biochem., 1987, 162, pp. 156−159.
- Christe M., Fritschi J., Lammle B. et al. Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. // Thromb Haemost 1984 Oct 31 — 52(2) :138−143.
- Coban E., Sari R., Ozdogan M. et al. Levels of plasma fibrinogen and d-dimer in patients with impaired fasting glucose // Exp Clin Endocrinol Diabetes 2005 Jan- 113(1): 35−7.
- Colwell J. Treatment for the procoagulant state in type 2 diabetes. // Endocrinol Metab Clin North Am 2001 Dec- 30(4): 1011−1030.
- Cooper M.E., Vranes D., Youssef S., Stacker S.A., Cox A.J., Rizkalla B. et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. // Diabetes. 1999 Nov- 48(11): 2229−39.
- Coppola G., Corrado E., Muratori I. et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM // Int J Cardiol. 2006 Jan 4- 106(1): 16−20.
- Corbella E., Miragliotta G., Masperi R. et al. Platelet aggregation and antithrombin III levels in diabetic children. // Haemostasis 1979 — 8(1): 3037.
- Cross M.5 Claesson-Welsh L. FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. // TRENDS in Pharmacological Sciences, Vol.22, No 4, April, 2001.
- Dallinger K., Jennings P., Toop M., Gyde O., Barnett A. Platelet aggregation and coagulation factors in insulin dependent diabetics with and without microangiopathy. // Diabet Med 1987 Jan-Feb- 4(1): 44−48.
- Davi G., Ciabattoni G., Consoli A. et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. // Circulation 1999 Jan 19- 99(2): 224−229.
- De Taeye B., Smith LH., Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease // Curr Opin Pharmacol 2005 Apr- 5(2): 149−54.
- Donders S., Lustermans F., van Wersch J. The effect of microalbuminuria on glycaemic control, serum lipids and haemostasis parameters in non-insulin-dependent diabetes mellitus. //Ann Clin Biochem 1993 Sep — 30(Pt5): 439−444.
- Duh E., Aiello L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. // Diabetes. 1999 Oct- 48(10): 1899−906.
- Duncan B., Schmidt M., Offenbacher S. et al. Factor VIII and other hemostatic variables are related to incident diabetes in adults. Tha Atherosclerosis Risk in Communities (ARIC) study. // Diabetes Care 1999 May- 22(5): 767−772.
- Dunn EJ., Ariens RA., Grant PJ. The influence of type 2 diabetes on fibrin structure and function // Diabetologia 2005 Jun- 48(6): 1198−206. Epub 2005 Apr 29.
- Dunn EJ., Grant PJ. Type 2 diabetes: an atherothrombotic syndrome // Curr Mol Med 2005 May- 5(3): 323−32.
- Elder G., Mayne E., Daly J. et al. Antithrombin III activity and other coagulation changes in proliferative diabetic retinopathy. // Haemostasis 1980- 9(5): 288−296.
- Erem C., Hacihasanoglu A., Celik S. et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications // Med Princ Pract 2005 Jan-Feb- 14(1): 22−30.
- Esser P., Weller M., Heimann K., Wiedemann P. Thrombospondin and its importance in proliferative retinal diseases. // Fortschr Ophthalmol 1991- 88(4): 337−340.
- Fattah MA., Shaheen MH., Mahfouz MH. Disturbances of haemostasis in diabetes mellitus // Dis Markers 2003−2004- 19(6): 251−8.
- Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. // Kidney Int, Vol 56 (1999): 794−814.
- Fisher B., Quin J., Rumeley A. et al. Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects. // Clin Sci (Lond) 1991 May- 80(5): 525−531.
- Ford I., Singh T., Kitchen S., Makris M., Preston F. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. // Diabet Med 1991 May- 8(4): 322−329.
- Funatsu H., Yamashita H., Ikeda T., Mimura T., Eguchi S., Hon S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. // Ophthalmology. 2003 Sep- 110(9): 1690−6.
- Gabazza E., Takeya H., Deguchi H. et al. Protein C activation in NIDDM patients. // Diabetologia 1996 Dec- 39(12): 1455−1461.
- Galajda P., Martinka E., Kubisz P. et al. Hemostasis in patients with diabetes mellitus. Markers of endothelial dysfunction. // Vnitr Lek 1996 Oct- 42(10): 676−679.
- Ganda O., Arkin C. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes.// Diabetes Care, Vol 15, Issue 10 12 451 250.
- Gandolfo G., De Angelis A., Torresi M. Determination of antitrombin III activities by different methods in diabetic patients. // Haemostasis 1980- 9(1): 15−19.
- Gomes MB., Nogueira VG. Acute-phase proteins and microalbuminuria among patients with type 2 diabetes // Diabetes Res Clin Pract 2004 Oct- 66(1): 31−9.
- Gosk-Bierska I., Adamiec R., Alexewicz P., Wysokinski W. Coagulation in diabetic and non-diabetic claudicants.// Int Angiol 2002 Jun- 21(2): 128−133.
- Graeven U., Fiedler W., Karpinski S., Ergun S. et al. Melanoma-associated expression of vascular endothelia growth factor and its receptors FLT-1 and KDR. // J. Cancer Res. Clin. Oncol., 1999, 125, pp. 621−629.
- Grant P., Stickland M., Davies J., Prentice C. Effect of controlled hyperglycaemia on factor VIII concentrations in insulin dependent diabetes mellitus. //Thromb Res 1988 Apr 1- 50(1): 157−162.
- Grant P., Stickland M., Wiles P. et al. Hormonal control of haemostasis during hypoglycaemia in diabetes mellitus. // Thromb. Haemost. 1987 Jun 3 — 57(3): 341−344.
- Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular disease, and chronic inflammation. // Pharmacological Reviews, Vol. 52 N2: 237−268.
- Grone H.J., Simon M., Grone E.F. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. // J. Pathol. 1995 Nov- 177(3): 259−67.
- Gruden G., Olivetti C., Cavallo-Perin P. et al. Activated protein C resistance in type I diabetes. // Diabetes Care Vol.20, Issue 3 424−425.
- Guillausseau P., Dupuy E. Antithrombotic agent and diabetes. Benefits and recommendations for use.// Arch Mai Coeur Vaiss 1996 Nov- 89(11 Suppl): 1557−1561.
- Guisti C., Schiaffmi R., Brufani C. et al. Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients. // Br J Ophthalmol 2000 Jun- 84(6): 591−595.
- Hahn L., Mattsson L., Andersson B., Tengborn L. The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus. // Blood Coagul Fibrinolysis 1999 Mar- 10(2): 81−86.
- Harbarchuk O. The coagulogram characteristics of patients with non-insulin-dependent diabetes mellitus. // Lik. Sprava 1999 Jan-Feb- (1): 62−64.
- Hariawala M., Sellke F. Angiogenesis and the heart: therapeutic implications. // J. R. Soc. Med 1997, 90: 307−311.
- Ho C.H., Jap T.S. Do smoking and diabetes change the hemostatic parameters? a study in the Chinese people. // Thromb Res 1994 Dec 15- 76(6): 569−576.
- Hogemann B., Balleisen L., Rauteberg J., Voss B., Gerlach U. Basement membrane components (7S collagen, laminin PI) are increased in sera ofndiabetics and activate platelets in vitro. // Haemostasis 1986- 16(6): 428 432.
- Hong KH, Ryu J., Han KH. Monocyte chemoattractant protein-1 induced angiogenesis is mediated by vascular endothelial growth factor-A.// Blood. 2005 Feb 15- 105(4): 1405−7. Epub 2004 Oct
- Hornsby W., Boggess K., Lyons T. et al. Hemostatic alterations with exercise conditioning in NIDDM. // Diabetes Care Vol.13, Issue 2 87−92.
- Hovind P., Tarnow L., Oestergaadr P.B., Parving H.H. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. // Kidney Int. Suppl. 2000 Apr- 75: S56−61.
- Hu J., Wei W., Din G., Yuan L., Liu Z. Variations and clinical significance of coagulation and fibrinolysis parameters with diabetes mellitus.//J Tongji Med Univ 1998- 18(4): 233−235.
- Ibrahim HA., El-Meligi AA., Abdel-Hamid M. et al Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus // Med Sei Monit 2004 Mar- 10(3): CR85−9.
- Ioannidis I., Tsoukala C., Panayotopoulou C. et al. Effects of glibenclamide on postprandial coagulation activation. // Nutr Metab Cardiovasc Dis 1999 Aug- 9(4): 204−207.
- Ishida S., Usui T., Yamashiro K., Kaji Y., Ahmed E., Carrasquillo K.G., Amano S. et al. VEGF164 is proinflammatory in the diabetic retina. // Invest Ophthalmol Vis Sei. 2003 May- 44(5): 2155−62.
- Isner J.M., Ropper A., Hirst K. VEGF gene transfer for diabetic neuropathy. // Hum Gene Ther. 2001 Aug 10- 12(12): 1593−4.
- Iwase E., Tawata M., Aida K. et al. a cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. // Metabolism 1998 Jun- 47(6): 699−705.
- Juhan-Vague I., Alessi M., Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. // Ann Med 1996 Aug- 28(4): 371−380.
- Kajita K., Ishizuka T., Miura A. et al. Increased platelet aggregation in diabetic patients with microangiopathy despite good glycemic control. // Platelets 2001 Sep- 12(6): 343−351.
- Kang D.H., Johnson R.J. Vascular endothelial factor: a new player in the pathogenesis of renal fibrosis. // Curr Opin Nephrol Hypertens. 2003 Jan- 12(1): 43−9.
- Kato K., Yamada D., Midorikawa S. et al. Improvement by the insulin-sensitizing, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. // Metabolism 2000 May- 49(5): 662−665.
- Kimura I., Honda R., Okai H., Okabe M. Vascular endothelial growth factor promotes cell-cycle transition from GO to Gl phase in subcultured endothelial cells of diabetic rat thoracic aorta. // Jpn. J. Pharmacol. 2000 May- 83(l):47−55.
- Knobl P., Schernthaner G., Schnack C. et al. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type (non-insulin-dependent) diabetic patients. // Diabetologia 1993 Oct- 36(10): 1045−1050.
- Knobler II., Savion N., Shenkman B. et al. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. // Thromb Res 1998 May 15- 90(4): 181−190.
- Krugluger W., Kopp H.P., Schernthaner G., Hopmeier P. Enhanced anticoagulant response to activated protein C in patients with IDDM. // Diabetes Vol. 44, Issue 9 1033−1037.
- Kruszynska Y., Yu J., Olefsky J., Spbel B. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. // Diabetes 2000 Apr- 49(4): 633−639.
- Kubisz P., Parizek M., Cronberg S. Apolipoprotein B and platelet function in diabetes mellitus. // Haemostasis 1986- 16(6): 424−427.
- Kvasnicka J., Skriha J., Perusicova J. et al. Haemostasis, cytoadhesive molecules (sE-selectin and sICAM-1) and inflammatory markers in noninsulin dependent diabetes mellitus (NIDDM).// Sb Lek 1998- 99(2): 97 101.
- Lee HB., Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy //Nephrology (Carlton) 2005 Oct- 10 Suppl: SI 1−3.
- Lengyel Z., Voros P., Toth LK. et al. Urinary albumin excretion is correlated to fibrinogen levels and protein S activity in patients with type 1 diabetes mellitus without overt diabetic nephropathy //Wein Klin Wochenschr 2004 Apr 30- 116(7−8): 240−5.
- Lenz T., Haak T., Malek J., Grone H.J., Geiger H., Gossmann J. Vascular endothelial growth factor in diabetic nephropathy. // Kidney Blood Press. Res. 2003- 26(5−6):338−43.
- Leurs P., Stolk R., Hamulyak K. et al. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impared glucose tolerance and type 2 diabetes. // Diabetes Care 2002 Aug- 25(8): 1340−1345.
- Li Y., Woo V., Bose R. Platelet hyperactivity and abnormal Ca (2+) homeostasis in diabetes mellitus. // Am J Physiol Heart Circ Physiol 2001 Apr- 280(4): H1480−489.
- Lin H., Huang S., Mi X., Sha Z. Effects of Cilazapril on the expression of vascular endothelial growth factor and intercellular adhesion molecule-1 in diabetic rat glomeruli. // Sichuan Da Xue Xue Bao Yi Ban 2003 Oct- 34(4): 694−7.
- Lowe G., Ghafour I., Belch J. et al. Increased blood viscosity in diabetic proliferative retinopathy. // Diabetes Res 1986 Feb- 3(2): 67−70.
- Lu M., Adamis A.P. Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. // Ophthalmol Clin North Am. 2002 Mar- 15(1): 69−79.
- Lupu C., Calb M., Ionescu M., Lupu F. Enchanced protrombin and intrinsic factor X activation on blood platelets from diabetic patients // Thromb Haemost. 1993 Oct 18- 70(4): 579−83.
- Mansfield M., Heywood D., Grant P. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. // Arteriosclerosis, Thrombosis, and Vascular Biology 1996- 16:160−164.
- Martin A., Komada M.R., Sane D.C. Abnormal angiogenesis in diabetes mellitus. // Med. Res. Rev. 2003 Mar- 23(2): 117−45.
- McGill J., Schneider D., Arfken C. et al. Factors responsible for impared fibrinolysis in obese subjects and NIDDM patients. // Diabetes, Vol 43, Issue 1 104−109.
- Melidonis A., Stefanidis A., Tournis S. et al. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. // Clin Cardiol 2000 Mar- 23(3): 160 164.
- Metcalf P.A., Folsom A.R., Davis C.E., Wu K.K., Heiss G. Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus. // Diabetes Res Clin Pract 2000 Jan- 47(1): 25−35.
- Missov R., Stolk R., van der Bom et al. Plasma fibrinogen in NIDDM: the Rotterdam study.//Diabetes Care 1996- 19:157−8211- 159.
- Misz M., Beck P., Udvardy M., Rak K. Haemostasis in diabetics. // Acta Med Hung 1984- 41(2−3): 93−102.
- Mojto V. Fibrinogen and diabetic microangiopathy. // Vnitr Lek 1997 Feb- 43(2): 81−86.
- Mormile A., Veglio M., Gruden G. et al. Physiological inhibitors of blood coagulation and prothrombin fragment F 1+2 in type 2 diabeticpatients with normoalbuminuria and incipient nephropathy. // Acta Diabetol 1996 Sep- 33(3): 241−245.
- Nenci G., Paliani U. Diabetes, coagulation and vascular events. // Recenti Prog Med 2000 Feb- 91(2): 86−90.
- Nordt T., Bode C. Impared endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches. // Semin Thromb Hemost 2000- 26(5): 495−501.
- O’Donnel M., Le Guen C., Lawson N., Gyde O., Barnett A. Platelet behavior and haemostatic variables in type 1 (insulin-dependent) diabetic patients with and without albuminuria. // Diabet Med 1991 Aug-Sep- 8(7): 624−628.
- Ostermann H., van de Loo J. Factors of the hemostatic system in diabetic patients. A survey of controlled studies. // Haemostasis 1986- 16(6): 386−416.
- Ouvina S., La Greca R., Zanaro N. et al. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. // Thromb Res 2001 Apr- 102(2): 107−114.
- Pandolfi A., Cetrullo D., Polishuk R. et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. // Arteriosclerosis, Thrombosis and Vascular Biology 2001- 21: 1378−1382.
- Panutsopulos D., Papalambros E., Sigala F., Zafiropoulos A. et al. Protein and mRNA expression levels of VEGF-A and TGF-betal in different types of human coronary atherosclerotic lesions // Int J Mol Med. 2005 Apr- 15(4):603−10
- Panutsopulos D., Zafiropoulos A, Krambovitis E. et al. Periferal monocytes from diabetic patients with coronary disease display increased bFGF and VEGF mRNA expression. // J Transl Med. 2003 Oct 6−1(1):6.
- Potter van Loon B., Kluft C., Radder J., Blankenstein M., Meinders A. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin-resistance. //Metabolism 1993 Aug- 42(8):945−949.
- Rauch U., Ziegler D., Piolot R. et al. Platelet activation in diabetic cardiovascular autonomic neuropathy. // Diabet Med 1999 Oct- 16(10): 848 852.
- Reid H., Vigilance J., Wright-Pascoe R., Choo-Kang E. The influence of persistent hyperglycaemia on hyperfibrinogenaemia and hyperviscosity in diabetes mellitus. // West Indian Med J 2000 Dec- 49(4): 281−284.
- Renner W., Pilger E. Simultaneous in vivo quantitation of vascular endothelial growth factor mRNA splice variants. // J Vase Res. 1999 Mar-Apr- 36(2): 133−8.
- Rigla M., Fontcuberta J., Mateo J. et al. Physical training decreases plasma thrombomodulin in type I and type II diabetic patients. // Diabetologia 2001 Jun- 44(6): 693−699.
- Rigla M., Mateo J., Fontcuberta J. et al. Normalisation of tissue factor pathway inhibitor activity after glycaemic control optimization in type I diabetic patients. // Thromb Haemost 2000 Aug- 84(2): 223−227.
- Rose D., Drewniak W., Kotschy M. et al. Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes. // Pol Merkuriusz Lek 1997 Jan- 2(7): 24−25.
- Roshan B., Toiler G., Weinrauch L. et al. Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease. //Metabolism2000 Jan- 49(1): 88−91.
- Saishin Y., Saishin Y., Takahashi K., Lima e Silva R., Hylton D., Rudge J.S. et al. VEGF-TRAP (R1R2) suppresses choroidalneovascularisation and VEGF-induced breakdown of the blood-retinal barrier. //J Cell Physiol. 2003 May- 195(2): 241−8.
- Sagcan A., Nalbantgil S., Omay S., Akin M. The effect of type II diabetes mellitus on platelet aggregation in patients who underwent percutaneous transluminal coronary angioplasty. // Coron Artery Dis 2002 Feb- 13(1): 45−48.
- Sakamoto T., Ito S., Yoshikawa H. et al. Tissue factor increases in the aqueous humor of proliferative diabetic retinopathy. // Graefes Arch Clin Exp Ophthalmol 2001 Nov- 239(11): 865−871.
- Sasso F.C., Carbonara O., Persico E., D’Ambrosio R., Coppola L. et al. Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats. // Metabolism. 2003 Jun- 52(6): 675−8.
- Schaeffer G., Wascher T., Kostner G., Graier W. Alterations in platelet Ca2+ signaling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. // Diabetologia 1999 Feb- 42(2): 167−176.
- Siluk D., Kaliszan R., Haber P. et al. Antiaggregatory activity of hypoglycaemic sulphonylureas. // Diabetologia 2002 Jul- 45(7): 1034−1037.
- Small M., Douglas J., Lowe G., MacCuish A., Forbes C. Effect of insulin therapy on coagulation and platelet function in type II (non-insulin-dependent) diabetes mellitus. // Haemostasis 1986 — 16(6): 417−423.
- Small M., Lowe G., MacCuish A., Forbes C. Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control. // Q J Med 1987 Dec- 65(248): 1025−1031.
- Smolensky V., Bokarev I., Velikov V. et al. Detection of solublefibrin monomer complexes and of platelet factor 4 in the plasma of patients with diabetes mellitus. // Folia Haematol Int Mag Klin Morphol Blutforsch 1979 — 106(5−6): 879−884.
- Sobel B.E., Tilton L., Neimane D. et al. Increased tissue-type plasminogen activator: a facade in the fibrinolytic system in type 2 diabetes // Coron Artery Dis 2005 Feb- 16(1): 31−5.
- Sobel B. Effects of glycemic control and other determinants on vascular disease in type 2 diabetes. // Am J Med 2002 Oct 28- 113 Suppl 6A: 12S-22S.
- Sobel B. The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. // Proc Assoc Am Physicians 1999 Jul-Aug- 111(4): 313−318.
- Sroczynski J., Krupa G., Chelmecka E., .Galwas B., Matyszczyk B. Some parameters of hemostasis in diabetic patients. // Pol Tyg Lek 1989 May 1−8-44(18−19): 420−422.
- Standeven K., Ariens R., Whitaker P. et al. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. // Diabetes 2002 Jan- 51(1): 189 197.
- Sueishi K., Hata Y., Murata T., Nakagawa K., Ishibashi T., Inomata H. Endothelial and glial cell interaction in diabetic retinopathy via the function of vascular endothelial growth factor (VEGF). // Pol. J. Pharmacol. 1996 May-Jun- 48(3):307−16.
- Sun X., Zhou X., Yan H. Hypercoagulation aggravates renal dysfunction in patient with diabetic nephropathy. // Zhonghua Xue Ye Xue Za Zhi 2001 Sep- 22(9): 476−477.
- Takebayashi K., Suetsugu M., Matsumoto R. Correlation of high-sensitivity C-reactive protein and plasma fibrinogen with individual complications in patients with type 2 diabetes // South Med J. 2006 Jan- 99(l):23−7.
- Telejko B., Tomasiak M., Stelmach H., Kinalska I. Platelet sodium-proton exchanger and phospholipid-dependent procoagulant activity in patients with type 2 diabetes. // Metabolism 2003 Jan- 52(1): 102−106.
- Telejko B., Tomasiak M., Stelmach H., Kinalska I. Sodium-proton exchanges and platelet procoagulant activity in type 1 diabetic patients. // Pol Arch Med Wewn 2002 Jun- 107(6): 533−537.
- Telejko B., Zonenberg A., Borejszo I., Kinalska I. Some parameters of hemostasis and fibrinolysis in diabetic patients. // Pol Arch Med Wewn 1998 Aug- 100(2): 133−138.
- Testa R., Bonfigli A., Pieri C. et al. A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein (a) in non-insulin-dependent diabetes mellitus without complications. // Int J Clin Lab Res 1998- 28(3): 187−191.
- Tilton R.G. Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. // Microsc Res Tech. 2002 Jun 1- 57(5): 390 407.
- Tomanek R., Schatteman B.C. Angiogenesis: new insights and therapeutic potential. // The anatomical record (new ANAT.) 261: 126−135.
- Toth L., Szenasi P., Varsanyi-Nagy M. et al. Relatioship between platelet hyperactivation and dyslipoproteinemia in diabetic nephropathy. // Orv Hetil 1992 Apr 26- 133(17): 1037−1040.
- Toth L., Szenasi P., Varsanyi M. et al. Elevated levels of plasma and urine beta-thromboglobulin or thromboxane-B2 as markers of real platelet hyperactivation in diabetic nephropathy. // Haemostasis 1992- 22(6): 334 339.
- Tschoepe D., Ostermann H., Huebinger A. et al. Elevated platelet activation in type I diabetics with chronic complications under long-term near-normoglycemic control.//Haemostasis 1990- 20(2): 93−98.
- Tsilibary E.C. Microvascular basement membranes in diabetes mellitus. // J Pathol. 2003 Jul- 200(4): 537−46.
- Vambergue A., Rugeri L., Gaveriaux V. et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index and age // Thromb Res 2001 Mar 1- 101(5) 367−75.
- Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. // Seminars in Cancer biology, Vol. 9, 1999: 211−220.
- Vinik A., Erbas T., Park T., Nolan R., Pittenger G. Platelet dysfunction in type 2 diabetes. // Diabetes Care 2001 Aug- 24(8): 14 761 485.'
- Vukovich T., Proidl S., Knobl P. et al. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. // Thromb Haemost 1992 Sep 7- 68(3): 253−256.
- Vukovich T, Schernthaner G. Decreased protein C levels in patients with insulin-dependent type I diabetes mellitus. // Diabetes Vol.35, Issue 5 617−619.
- Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. // Cardiovasc. Res. 2001 Feb 16- 49(3): 554−60.
- Wang Z., Zhang J., Zhang B. Vascular endothelial growth factor gene expression in patients' ischemic skeletal muscle with diabetic foot. // Zhonghua Yu Fang Yi Xue Za Zhi. 2002 Nov- 36(7): 505−7.
- Watala C., Boncer M., Golanski J. et al. Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus. // Eur J Haematol 1998 Nov- 61(5): 319−326.
- Watala C., Gwozdzinski K., Pluskota E. et al. Diabetes mellitus alters the effect of peptide and protein ligands on membrane fluidity of blood platelets. //Thromb Haemost 1996 Jan — 75(1): 147−153.
- Wattanakit K., Folsom AR., Selvin E. et al. Risk factors for peripheral arterial disease incidence in persons with diabete: the Atherosclerosis Risk in Communities (ARIC) Study//Atherosclerosis 2005 Jun- 180(2): 389−97. Epub 2005 Jan 25.
- Watze H., Schernthaner G., Schnack C. et al. Coagulation factors of contact phase of haemostasis are normal in well-controlled type-I diabetic patients despite presence of diabetic retinopathy. // Diabetes Res 1988 Apr- 7(4): 197−200.
- Webb NJ., Myers CR., Watson CJ., Bottomley MJ., Brenchley PE. Activated human neutrophils express vascular endothelial growth factor (VEGF) // Cytokine. 1998 Apr- 10(4): 254−7
- Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? // Miner Electrolyte Metab. 1998- 24(6): 400−5.
- Yang B., Cross DF., Ollerenshaw M. et al. // J Diabetes Complications. 2003 Jan-Feb- 17(1): 1−6.
- Zaslavskaia R., Tulemisov E., Teiblium M. Effects of aspirin standard therapy and chronotherapy on circadian organization of hemocoagulation in patients with insulin-dependent diabetes mellitus. // Klin Med (Mosk) 2002−80(2): 43−46.